Human immunodeficiency virus type 1 Gag, Pol, Env, and Nef antigens (HIV-1 Gag/Pol/Env/Nef)

Human immunodeficiency virus type 1 (HIV-1) Gag, Pol, Env, and Nef are the primary protein components of the virus, collectively serving as the foundation for most therapeutic and prophylactic vaccine strategies. Gag (Group-specific antigen) provides the structural framework for viral assembly and budding, while Pol (Polymerase) encodes essential enzymes including reverse transcriptase, integrase, and protease (UniProt: P04591, P03367). Env (Envelope) consists of surface glycoproteins gp120 and gp41, which are critical for viral attachment and fusion with host CD4+ T cells (UniProt: P04578). Nef (Negative regulatory factor) is an accessory protein that facilitates immune evasion by downregulating MHC-I and CD4 receptors on the host cell surface (UniProt: P04601). In clinical development, these antigens are often delivered via DNA plasmids, viral vectors, or mRNA to elicit broad, multi-epitope cellular and humoral immune responses (NIH/NIAID). This multi-antigen approach is designed to overcome the high genetic diversity and mutation rate of HIV-1, aiming for a functional cure by reducing the latent viral reservoir.

Other names

HIV-1 polyproteinsHIV-1 structural and regulatory proteinsGag-Pol-Env-Nef vaccine antigensHIV-1 polyprotein (Gag-Pol)

The mechanism of action involves the presentation of viral epitopes by MHC class I and II molecules following the expression of the Gag, Pol, Env, and Nef antigens by host cells or delivery via vaccine platforms. This process primes the immune system to generate cytotoxic T lymphocytes (CTLs) that target infected cells and B cells that produce neutralizing antibodies, thereby controlling viral replication and potentially clearing the latent reservoir (NIH/NIAID; PubMed: 28416512).